JP6693873B2 - Ｇｄ２陽性がんを処置するための製剤および方法 - Google Patents

Ｇｄ２陽性がんを処置するための製剤および方法 Download PDF

Info

Publication number
JP6693873B2
JP6693873B2 JP2016533187A JP2016533187A JP6693873B2 JP 6693873 B2 JP6693873 B2 JP 6693873B2 JP 2016533187 A JP2016533187 A JP 2016533187A JP 2016533187 A JP2016533187 A JP 2016533187A JP 6693873 B2 JP6693873 B2 JP 6693873B2
Authority
JP
Japan
Prior art keywords
treatment
antibody
patient
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016533187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539122A5 (enExample
JP2016539122A (ja
Inventor
ハンス・ロイプナー
オリヴァー・ムッチュレヒナー
ルート・ラデンシュタイン
イザベル・クリアー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeiron Biologics GmbH
Original Assignee
Apeiron Biologics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13193953.0A external-priority patent/EP2875827A1/en
Priority claimed from CA2834000A external-priority patent/CA2834000A1/en
Priority claimed from US14/182,776 external-priority patent/US10294305B2/en
Application filed by Apeiron Biologics GmbH filed Critical Apeiron Biologics GmbH
Publication of JP2016539122A publication Critical patent/JP2016539122A/ja
Publication of JP2016539122A5 publication Critical patent/JP2016539122A5/ja
Application granted granted Critical
Publication of JP6693873B2 publication Critical patent/JP6693873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016533187A 2013-11-21 2014-11-21 Ｇｄ２陽性がんを処置するための製剤および方法 Active JP6693873B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201314086696A 2013-11-21 2013-11-21
CA2834000 2013-11-21
EP13193953.0 2013-11-21
EP13193953.0A EP2875827A1 (en) 2013-11-21 2013-11-21 Preparations and methods for treating a GD2 positive cancer
US14/086,696 2013-11-21
CA2834000A CA2834000A1 (en) 2013-11-21 2013-11-21 Method for treating a gd2 positive cancer
US14/182,776 2014-02-18
US14/182,776 US10294305B2 (en) 2012-06-18 2014-02-18 Method for treating a GD2 positive cancer
PCT/EP2014/075315 WO2015075194A1 (en) 2013-11-21 2014-11-21 Preparations and methods for treating a gd2 positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019142173A Division JP7139293B2 (ja) 2013-11-21 2019-08-01 Ｇｄ２陽性がんを処置するための製剤および方法

Publications (3)

Publication Number Publication Date
JP2016539122A JP2016539122A (ja) 2016-12-15
JP2016539122A5 JP2016539122A5 (enExample) 2017-08-31
JP6693873B2 true JP6693873B2 (ja) 2020-05-13

Family

ID=53179006

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016533187A Active JP6693873B2 (ja) 2013-11-21 2014-11-21 Ｇｄ２陽性がんを処置するための製剤および方法
JP2019142173A Active JP7139293B2 (ja) 2013-11-21 2019-08-01 Ｇｄ２陽性がんを処置するための製剤および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019142173A Active JP7139293B2 (ja) 2013-11-21 2019-08-01 Ｇｄ２陽性がんを処置するための製剤および方法

Country Status (19)

Country Link
US (3) US10995147B2 (enExample)
EP (2) EP3620173A1 (enExample)
JP (2) JP6693873B2 (enExample)
AU (2) AU2014351796B2 (enExample)
CA (1) CA2930285A1 (enExample)
CY (1) CY1122508T1 (enExample)
DK (1) DK3071220T3 (enExample)
EA (1) EA201691055A1 (enExample)
ES (1) ES2768649T3 (enExample)
HR (1) HRP20200128T1 (enExample)
HU (1) HUE047920T2 (enExample)
LT (1) LT3071220T (enExample)
NZ (1) NZ720273A (enExample)
PL (1) PL3071220T3 (enExample)
PT (1) PT3071220T (enExample)
RS (1) RS59817B1 (enExample)
SI (1) SI3071220T1 (enExample)
SM (1) SMT202000027T1 (enExample)
WO (1) WO2015075194A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218359A (ja) * 2013-11-21 2019-12-26 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ Ｇｄ２陽性がんを処置するための製剤および方法
US11597775B2 (en) 2013-11-21 2023-03-07 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
RU2663104C1 (ru) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
JP2020534370A (ja) * 2017-09-21 2020-11-26 ユーエムセー ユトレヒト ホールディング ベイフェイＵＭＣ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 神経芽腫の治療のための抗ｇｄ２抗体
JP2023532753A (ja) * 2020-07-06 2023-07-31 イーユーエスエー ファーマ （ユーケー） リミテッド Ｇｄ２陽性がんを治療するための方法
WO2026053122A1 (en) * 2024-09-04 2026-03-12 Dana-Farber Cancer Institute, Inc. Methods of treating retinoid responsive cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
WO2007045465A1 (en) 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
EP1916257A1 (en) 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
JP5654986B2 (ja) 2008-06-30 2015-01-14 モーフオテク・インコーポレーテツド 抗ｇｄ２抗体並びにそれに関連する方法及び使用
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
JP5623999B2 (ja) 2010-08-31 2014-11-12 パナソニック株式会社 電子装置
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
EP4218811A1 (en) 2012-06-18 2023-08-02 Apeiron Biologics AG Method for treating a gd2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
EA201691055A1 (ru) 2013-11-21 2016-11-30 Апейрон Биолоджикс Аг Препараты и способы лечения gd2-положительного рака

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218359A (ja) * 2013-11-21 2019-12-26 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ Ｇｄ２陽性がんを処置するための製剤および方法
US11492412B2 (en) 2013-11-21 2022-11-08 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
US11597775B2 (en) 2013-11-21 2023-03-07 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer

Also Published As

Publication number Publication date
EP3620173A1 (en) 2020-03-11
EP3071220B1 (en) 2019-12-25
AU2014351796B2 (en) 2020-02-27
JP7139293B2 (ja) 2022-09-20
PT3071220T (pt) 2020-02-03
LT3071220T (lt) 2020-02-25
JP2016539122A (ja) 2016-12-15
ES2768649T3 (es) 2020-06-23
EA201691055A1 (ru) 2016-11-30
AU2014351796A2 (en) 2016-08-11
NZ720273A (en) 2022-02-25
EP3071220A1 (en) 2016-09-28
HK1223039A1 (en) 2017-07-21
AU2014351796A1 (en) 2016-05-26
SI3071220T1 (sl) 2020-03-31
CY1122508T1 (el) 2021-05-05
US20200332021A1 (en) 2020-10-22
SMT202000027T1 (it) 2020-03-13
AU2020203346A1 (en) 2020-06-11
US20210221909A1 (en) 2021-07-22
PL3071220T3 (pl) 2020-05-18
JP2019218359A (ja) 2019-12-26
HRP20200128T1 (hr) 2020-05-15
US11492412B2 (en) 2022-11-08
DK3071220T3 (da) 2020-02-10
RS59817B1 (sr) 2020-02-28
US20240158530A1 (en) 2024-05-16
US10995147B2 (en) 2021-05-04
CA2930285A1 (en) 2015-05-28
WO2015075194A1 (en) 2015-05-28
HUE047920T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
US20230340148A1 (en) Method for treating a gd2 positive cancer
JP7139293B2 (ja) Ｇｄ２陽性がんを処置するための製剤および方法
US9777068B2 (en) Method for treating a GD2 positive cancer
US20260132216A1 (en) Preparations and methods for treating a gd2 positive cancer
WO2022109302A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CA2834000A1 (en) Method for treating a gd2 positive cancer
EP2875827A1 (en) Preparations and methods for treating a GD2 positive cancer
HK1223039B (en) Preparations for treating a gd2 positive cancer
HK40022685A (en) Preparations and methods for treating a gd2 positive cancer
EA043975B1 (ru) Препараты и способы лечения gd2-положительного рака
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190801

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200416

R150 Certificate of patent or registration of utility model

Ref document number: 6693873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250